Graham Jonathan P

SEC source: 0001127602-21-014597 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,965

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,046 RSUs which will vest on 5/1/2021; 1,073 RSUs which will vest on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 897 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-011710 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,529

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 990 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-009478 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,670

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 838 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-004257 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,945

F1 · price: The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 838 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015860 · form4.xml · derivative · entry 2

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,633

Underlying: Common Stock · 27,633 shares

Expires 2030-05-05

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015860 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,656

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 439 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015544 · form4.xml · nonDerivative · entry 2

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,356

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; and 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 439 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015544 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,911

SEC source: 0001127602-20-014695 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,460

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,001 RSUs which vest in one installment on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; and 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 644 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-011867 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,008

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,001 RSUs which vest in one installment on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; 3,155 RSUs which vest in two installments of 1,041 on 4/27/2020 and 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; and 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 705 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-009708 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,571

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,001 RSUs which vest in one installment on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; 3,155 RSUs which vest in two installments of 1,041 on 4/27/2020 and 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; and 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 560 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-033708 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,853

F1 · price: The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,001 RSUs which vest in one installment on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; 3,155 RSUs which vest in two installments of 1,041 on 4/27/2020 and 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; and 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 442 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-031965 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,853

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 11/1/2021, 11/1/2022 and 11/1/2023, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,001 RSUs which vest in one installment on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; 3,155 RSUs which vest in two installments of 1,041 on 4/27/2020 and 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; and 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 442 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-026187 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,610

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,001 RSUs which vest in one installment on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; 3,155 RSUs which vest in two installments of 1,041 on 4/27/2020 and 4/27/2021 and one installment of 1,073 on 4/27/2022; and 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 375 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017648 · form4.xml · derivative · entry 3

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,568

Underlying: Common Stock · 27,568 shares

Expires 2029-05-03

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

SEC source: 0001127602-19-017648 · form4.xml · nonDerivative · entry 2

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,204

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 12,300 RSUs which vest on 8/4/2019; 1,001 RSUs which vest in one installment on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; 3,155 RSUs which vest in two installments of 1,041 on 4/27/2020 and 4/27/2021 and one installment of 1,073 on 4/27/2022; and 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,566 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017648 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,046

SEC source: 0001127602-19-017333 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,569

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 12,300 RSUs which vest in one equal installment of 12,300 on 8/4/2019; 1,972 RSUs which vest in two installments of 971 on 5/3/2019 and 1,001 on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; and 3,155 RSUs which vest in installments of 1,041 on 4/27/2020, 1,041 on 4/27/2021 and 1,073 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,647 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-013161 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,101

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 12,300 RSUs which vest in one equal installment of 12,300 on 8/4/2019; 1,972 RSUs which vest in two installments of 971 on 5/3/2019 and 1,001 on 5/3/2020; 3,075 RSUs which vest in installments of 1,014 on 5/1/2019, 1,015 on 5/1/2020 and 1,046 on 5/1/2021; and 3,155 RSUs which vest in installments of 1,041 on 4/27/2020, 1,041 on 4/27/2021 and 1,073 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,704 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-010655 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,123

F1 · balance_after: These shares include the following Restricted Stock Unites (RSUs) granted under the Company's equity plans: 12,300 RSUs which vest in one equal installment of 12,300 on 8/4/2019; 1,972 RSUs which vest in two installments of 971 on 5/3/2019 and 1,001 on 5/3/2020; 3,075 RSUs which vest in installments of 1,014 on 5/1/2019, 1,015 on 5/1/2020 and 1,046 on 5/1/2021; and 3,155 RSUs which vest in installments of 1,041 on 4/27/2020, 1,041 on 4/27/2021 and 1,073 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,528 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-18-024774 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,256

F1 · balance_after: These shares include the following Restricted Stock Unites (RSUs) granted under the Company's equity plans: 12,300 RSUs which vest in one equal installment of 12,300 on 8/4/2019; 1,972 RSUs which vest in two installments of 971 on 5/3/2019 and 1,001 on 5/3/2020; 3,075 RSUs which vest in installments of 1,014 on 5/1/2019, 1,015 on 5/1/2020 and 1,046 on 5/1/2021; and 3,155 RSUs which vest in installments of 1,041 on 4/27/2020, 1,041 on 4/27/2021 and 1,073 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,231 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-18-016534 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,366

F1 · balance_after: These shares include the following Restricted Stock Unites (RSUs) granted under the Company's equity plans: 24,600 RSUs which vest in two equal installments of 12,300 on 8/4/2018 and 8/4/2019; 1,972 RSUs which vest in two installments of 971 on 5/3/2019 and 1,001 on 5/3/2020; and 3,075 RSUs which vest in installments of 1,014 on 5/1/2019, 1,015 on 5/1/2020 and 1,046 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,735 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-18-015837 · form4.xml · derivative · entry 2

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,291

Underlying: Common Stock · 24,291 shares

Expires 2028-04-27

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.

SEC source: 0001127602-18-015837 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,756

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 24,600 RSUs which vest in two equal installments of 12,300 on 8/4/2018 and 8/4/2019; 2,942 RSUs which vest in three installments of 970 on 5/3/2018, 971 on 5/3/2019 and 1,001 on 5/3/2020; and 3,075 RSUs which vest in installments of 1,014 on 5/1/2019, 1,015 on 5/1/2020 and 1,046 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,787 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-17-025060 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,165

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 24,600 RSUs which vest in two equal installments of 12,300 on 8/4/2018 and 8/4/2019; 2,942 RSUs which vest in three installments of 970 on 5/3/2018, 971 on 5/3/2019 and 1,001 on 5/3/2020; and 3,075 RSUs which vest in installments of 1,014 on 5/1/2019, 1,015 on 5/1/2020 and 1,046 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,351 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-17-016749 · form4.xml · derivative · entry 2

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,233

Underlying: Common Stock · 27,233 shares

Expires 2027-05-01

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/1/2019, 5/13/2020 and 5/1/2021, respectively.

SEC source: 0001127602-17-016749 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,619

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 36,900 RSUs which vest in three equal installments of 12,300 on 8/4/2017, 8/4/2018 and 8/4/2019; 2,942 RSUs which vest in three installments of 970 on 5/3/2018, 971 on 5/3/2019 and 1,001 on 5/3/2020; and 3,075 RSUs which vest in installments of 1,014 on 5/1/2019, 1,015 on 5/1/2020 and 1,046 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,684 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-16-059550 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,748

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 36,900 RSUs which vest in three equal installments of 12,300 on 8/4/2017, 8/4/2018 and 8/4/2019; and 2,942 RSUs which vest in three installments of 970 on 5/3/2018, 971 on 5/3/2019 and 1,001 on 5/3/2020.

F2 · balance_after: These shares include 888 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-16-051289 · form4.xml · derivative · entry 2

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,045

Underlying: Common Stock · 25,045 shares

Expires 2026-05-03

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.

SEC source: 0001127602-16-051289 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,982

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 49,199 RSUs which vest in one installment of 12,299 on 8/4/2016 and three equal installments of 12,300 on 8/4/2017, 8/4/2018 and 8/4/2019; and 2,942 RSUs which vest in three installments of 970 on 5/3/2018, 971 on 5/3/2019 and 1,001 on 5/3/2020.

F3 · balance_after: These shares include 841 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credit on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-15-024173 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,199

F1 · balance_after: The Restricted Stock Units were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in four annual installments of 25% each on 8/4/2016, 8/4/2017, 8/4/2018 and 8/4/2019.

SEC source: 0000313616-15-000063 · edgar.xml · derivative · entry 7

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,926 shares

Expires 2022-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 23, 2012.

SEC source: 0000313616-15-000063 · edgar.xml · derivative · entry 6

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,806 shares

Expires 2021-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 23, 2011.

SEC source: 0000313616-15-000063 · edgar.xml · nonDerivative · entry 5

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,606

SEC source: 0000313616-15-000063 · edgar.xml · nonDerivative · entry 4

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,503

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.02, inclusive.

SEC source: 0000313616-15-000063 · edgar.xml · nonDerivative · entry 3

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,412

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.02, inclusive. The reporting person undertakes to provide to Danaher Corporation, any securityholder of Danaher Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4.

SEC source: 0000313616-15-000063 · edgar.xml · nonDerivative · entry 2

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,838

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000313616-15-000063 · edgar.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,032

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000313616-15-000062 · edgar.xml · derivative · entry 18

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,920 shares

Expires 2020-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 23, 2010.

SEC source: 0000313616-15-000062 · edgar.xml · derivative · entry 17

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 675 shares

Expires 2019-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 24, 2009.

SEC source: 0000313616-15-000062 · edgar.xml · derivative · entry 16

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,160 shares

Expires 2017-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 22, 2007.

SEC source: 0000313616-15-000062 · edgar.xml · nonDerivative · entry 11

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,106

SEC source: 0000313616-15-000062 · edgar.xml · nonDerivative · entry 10

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,781

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000313616-15-000062 · edgar.xml · nonDerivative · entry 9

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,106

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.02, inclusive.

SEC source: 0000313616-15-000062 · edgar.xml · nonDerivative · entry 8

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,026

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000313616-15-000062 · edgar.xml · nonDerivative · entry 7

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,106

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.06, inclusive. The reporting person undertakes to provide to Danaher Corporation, any securityholder of Danaher Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4.

SEC source: 0000313616-15-000062 · edgar.xml · nonDerivative · entry 6

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,266

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000313616-15-000062 · edgar.xml · derivative · entry 15

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,920

Underlying: Common Stock · 11,060 shares

Expires 2020-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 23, 2010.

SEC source: 0000313616-15-000062 · edgar.xml · derivative · entry 14

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 675

Underlying: Common Stock · 58,805 shares

Expires 2019-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 24, 2009.

SEC source: 0000313616-15-000062 · edgar.xml · derivative · entry 13

Graham Jonathan P · CIK 0001365306 · Senior VP & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 53,660 shares

Expires 2018-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 20, 2008.